DDInter1042 DDInter280
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients .
Canagliflozin {u} (Compound) resembles {v} (Compound) Dapagliflozin
Canagliflozin {u} (Compound) binds {v} (Gene) SLC5A1
Canagliflozin {u} (Compound) is included by {v} (Pharmacologic Class) Sodium-Glucose Transporter 2 Inhibitors
Canagliflozin {u} (Compound) causes {v} (Side Effect) Vulvitis
Canagliflozin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomefloxacin
Canagliflozin {u} may lead to a major life threatening interaction when taken with {v} Gatifloxacin
Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Canagliflozin (Compound) binds SLC5A1 (Gene)
Canagliflozin (Compound) is included by Sodium-Glucose Transporter 2 Inhibitors (Pharmacologic Class)
Canagliflozin (Compound) causes Vulvitis (Side Effect)
Canagliflozin may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin
Canagliflozin may lead to a major life threatening interaction when taken with Gatifloxacin